The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Tyrosinkinaseinhibitoren bei Patienten mit radiojodrefraktärem differenziertem Schilddrüsenkarzinom
Rendl, G., Schweighofer-Zwink, G., & Pirich, C. (2023) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-023-00185-4
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v1
Self-citationMeric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v2
Self-citationDe, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00002-7
Data from Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Gouda, M. A., Nelson, B. E., Buschhorn, L., Wahida, A., & Subbiah, V. (2023) · doi:10.1158/1078-0432.c.6626953
Companion and complementary diagnostics as tools of precision medicine
Jørgensen, J. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00042-3
Advances in Drug Therapy for Gastrointestinal Stromal Tumour
Liu, J., Li, J., Zhu, Y., Jing, R., Ding, S., Zhang, J., Zhao, L., Chen, Y., & Shen, J. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230505163151
Personalized therapy in pancreatic cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.020
Mae, H., Outani, H., Imura, Y., Chijimatsu, R., Inoue, A., Kotani, Y., Yasuda, N., Nakai, S., Nakai, T., Takenaka, S., et al. (2023) · doi:10.1158/2767-9764.c.6686778
Boyarskikh, U. A., Savostyanova, T. A., Oscorbin, I. P., & Филипенко, М. Л. (2023) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-023-05824-z
Pardo, P. L., Tristán, M. S., Podesta, M. M. C., & Francés, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.06.001
Оскорбин, И. П., Ivanov, A. A., Smertina, M. A., Демидова, И. А., Boyarskikh, U. A., Андреевич, К. А., Bakharev, S. Y., Samuilenkova, O. V., Vihlyanov, I. V., Кушлинский, Н. Е., et al. (2023) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-023-05842-x
Resolution on the results of the round table “NTRK-positive tumors: diagnosis and treatment”
Editorial, A. (2023) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2023-10-2-112-116
Mayoh, C., Mao, J., Xie, J., Tax, G., Chow, S., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., et al. (2023) · doi:10.1158/0008-5472.c.6767498
Data from Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Gouda, M. A., Nelson, B. E., Buschhorn, L., Wahida, A., & Subbiah, V. (2023) · doi:10.1158/1078-0432.c.6626953.v2
Systemic treatment of soft tissue sarcoma
Özer, L., Celayir, Ö. M., & Sungur, M. (2023) · Türk Ortopedi ve Travmatoloji Birliği Derneği · doi:10.5578/totbid.dergisi.2023.74
Farmaci innovativi per il trattamento del carcinoma tiroideo avanzato
Sapuppo, G., Gianì, F., Martorana, F., Gambero, F., & Pellegriti, G. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01362-y
Ottaiano, A., Sabbatino, F., Perri, F., Cascella, M., Santorsola, M., & Nasti, G. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01004-1
Review of International Approaches to Assessing and Financing Tumor-agnostic Drugs
Омельяновский, В. В., Никитина, А. В., Рыжова, О. Р., Мухортова, П. А., & Струнина, Ю. В. (2023) · Voprosy Onkologii · doi:10.37469/0507-3758-2023-69-5-805-814
猪爪, 隆. (2023) · Skin Cancer · doi:10.5227/skincancer.38.60
Genetic and Epigenetic Dysregulation in Environmental Disease
Ramos, K. S., Hassanin, A. A. I., & Wang, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00034-4
Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review
Panchal, I. I., Tripathi, R. K. P., Parmar, K., & Yadav, M. R. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266271225231203164309
Cipri, S., Fabozzi, F., Baldo, G. D., Milano, G. M., Boccuto, L., Carai, A., & Mastronuzzi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235794
Ex vivo tissue modelling informs drug selection for rare cancers
Lee, J., Ming, Z., Cheung, V. K.-Y., Pedersen, B., Wykes, J., Palme, C. E., Clark, J. J., Gupta, R., & Rizos, H. (2023) · International Journal of Cancer · doi:10.1002/ijc.34802
Molecular features of gastrointestinal stromal tumors “wild-type” (KIT/PDGFRA WT)
Мазуренко, Н. Н., Yugay, V. V., & Tsyganova, I. V. (2023) · Advances in molecular oncology · doi:10.17650/2313-805x-2023-10-4-61-75
Management of Metastic Liver Cancer
Stewart, C. L., Ho, F., Fong, Y., Davis, S. L., Lisa, L., Lindquist, J. D., Karukonda, P., Willett, C. G., & Czito, B. G. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch19
Speranza, D., Sapuppo, E., Aprile, G., Auriemma, A., Bergamo, F., Bianco, R., Bordonaro, R., Brandi, G., Brunetti, O., Carnaghi, C., et al. (2024) · Tumori Journal · doi:10.1177/03008916231222761
Les tumeurs des glandes salivaires associées à des transcrits de fusion
Lae, M. E., Lanic, M., Lépine, C., Hourseau, M., Benzerdjeb, N., Uro‐Coste, E., & Costes‐Martineau, V. (2024) · Annales de Pathologie · doi:10.1016/j.annpat.2023.12.012
Radioiodine Refractory Thyroid Cancer
Pitoia, F., Smulever, A., & Jerkovich, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-38605-3_14
High-grade osteosarcoma arising from a clinically aggressive infantile fibrosarcoma
Furtado, L. V., Santiago, T., Abramson, Z. R., Kacar, M., Shi, Z., Koo, S. C., Ruiz, R., Mostafavi, R. M., Krasin, M. J., Shulkin, B. L., et al. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209384
Self-citationMolekularpathologie gastrointestinaler Tumoren
Bedau, T., & Quaas, A. (2024) · Die Gastroenterologie · doi:10.1007/s11377-024-00777-9
Therapie des Ösophagus- und Magenkarzinoms: Aktuelle zielgerichtete systemische Optionen
Waidmann, O. (2024) · Deutsches Ärzteblatt · doi:10.3238/persgastro.2024.04.19.04
Kano, S., Tsushima, N., Suzuki, T., Hamada, S., Yasuda, K., Uchinami, Y., & Homma, A. (2024) · Toukeibu Gan · doi:10.5981/jjhnc.50.6
Ke, J., Cao, M., Zhang, W., Huang, H., Chen, P., Liu, J., Shan, D., Ke, J., Wang, Z., Liu, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1332522
One Case Report of Giant Mediastinal Spindle Cell Tumor with NTRK Rearrangement
陈, 毓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451651
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2024) · Gastro-News · doi:10.1007/s15036-024-3709-5
Desmoplastic small round cell tumor: clinical case and literature review
Наталенко, К. Е., & Korkina, A. A. (2024) · Clinical Case in Oncology · doi:10.62546/3034-1477-2024-2-1-45-56
Sforzin, I., Beal, J. R., & Moura, F. (2024) · Archives of Surgery and Clinical Research · doi:10.29328/journal.ascr.1001082
Métellus, P., Camilla, C., Bialecki, E., Beaufils, N., Vellutini, C., Pellegrino, E., Tomasini, P., Ahluwalia, M. S., Mansouri, A., Nanni, I., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382394
Chemotherapie, gezielte Therapie und Immuntherapie des metastasierten kolorektalen Karzinoms
Richard, M., Koch, C., & Trojan, J. (2024) · Die Gastroenterologie · doi:10.1007/s11377-024-00815-6
Drug Delivery System for Aflibercept Delivery in Metastatic Colorectal Cancer (MCRC)
Mousavi, S. M., Jalilvand, H., Mosaed, R., & Tabesh, H. (2024) · doi:10.61440/jge.2024.v2.21
Oneda, E., Astore, S., Gandolfi, L., Melocchi, L., & Zaniboni, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406287
Delaye, M., Neuzillet, C., & Sabourin, J. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.08.013
Sarradin, V., Digue, L., Vergèz, S., Thariat, J., Fakhry, N., Chabrillac, E., Bensadoun, R. J., Ferrand, F., & Even, C. (2024) · Annales françaises d Oto-rhino-laryngologie et de Pathologie Cervico-faciale · doi:10.1016/j.aforl.2023.06.015
Lee, S., Jeon, Y.-R., Shin, C., Kwon, S., & Shin, S. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i2.96876
Moratin, J., Ristow, O., Hoffmann, J., Held, T., Schröter, P., Kahnt, F., & Dieter, S. M. (2024) · Die Onkologie · doi:10.1007/s00761-024-01657-1
Jin, M., Kim, C. A., Jeon, M. J., Lee, Y., Sung, T., Kim, T. Y., Kim, W. B., Kim, W. G., & Song, D. E. (2024) · Research Square · doi:10.21203/rs.3.rs-5424201/v1
Betts, C., Kassardjian, A., & Amini, A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251317134
How I Treat Advanced Biliary Cancer
Mohan, A., & Sahai, V. (2025) · Advances in Oncology · doi:10.1016/j.yao.2025.01.002
Patel, H. B., Dave, R. H., Vadariya, S., Hirpara, H., & Patel, T. (2025) · Analytical Chemistry Letters · doi:10.1080/22297928.2025.2458045
Genetic Rearrangements in Brain Tumors: A View from NTRK
Jacobo, J. A., Wagner-Gutiérrez, N., Aristizabal, J., Vallejo, S., González, A., Bobadilla, I., Pineda, D., Arrieta, O. G., & Cardona, A. F. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1007388
Orientações Práticas sobre a Deteção de Sarcomas de Fusão NTRK: Estado Atual e Desafios Diagnósticos
Fernandes, I., Macedo, D., Gouveia, E. J., Ferreira, A. M., Lima, J., Lopez, D., Melo-Alvim, C., Carvalho, A., Freitas-Tavares, P., Rodrigues‐Santos, P., et al. (2025) · Acta Médica Portuguesa · doi:10.20344/amp.21925
European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’
Folprecht, G., Morfouace, M., Collienne, M., Salazar, R., Stein, A., Élez, E., Wagner, D., Arnold, D., Köhne, C. H., Ducreux, M. P., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100168
Hein, A., & Hissong, E. M. (2025) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2025.03.011
Chemotherapie, gezielte Therapie und Immuntherapie des metastasierten kolorektalen Karzinoms
Richard, M., Koch, C., & Trojan, J. (2025) · Die Radiologie · doi:10.1007/s00117-025-01455-9
Weller, M., Chiocca, E. A., Mueller, S., Yu, J. S., & von Deimling, A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198869702.003.0006
Medical Oncological Treatment of the Pediatric Patient
Bielack, S., Sparber‐Sauer, M., & Blattmann, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-77061-6_12
Self-citationTranslational transcriptomics for personalized oncology
Buzdin, A. A., Seryakov, A. P., Zolotovskaia, M., Sorokin, M., Tkachev, V., Giese, A., Sekacheva, M. I., Poddubskaya, E. V., Rozenberg, J. M., & Mohammad, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19110-7.00008-2
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_5
Molecular drivers in CNS metastatic disease
Kim, H., Chernet, S., Kumthekar, P., & Sharma, A. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.04.004
Durable Response in NTRK Fusion-Positive Advanced Salivary Gland Tumor: A Case Report
Alca, G. O., Loma, L. A., González, L., Vega, P., Abril, Y. L. N., & Sumarriva, D. (2025) · Case Reports in Oncology · doi:10.1159/000545744
Molecularly driven therapies in the treatment of primary brain tumors
Nasany, R. A., & de la Fuente, M. I. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.05.005
Pathology Update of Rare or Recently Defined Entities
Lee, V. K. M., Rekhi, B., Wang, J., Omar, N. B., & Mok, Y. (2025) · Springer eBooks · doi:10.1007/978-981-96-2163-7_32
Thyroid Imaging and Radionuclide Therapy
Aggarwal, P., Kaur, G., Sood, A. K., & Mittal, B. R. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00342
Moratin, J., Ristow, O., Hoffmann, J., Held, T., Schröter, P., Kahnt, F., & Dieter, S. M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0990-1
Gut-Brain Axis and Colorectal Cancer: Neuroimmune Interactions
Prasad, A., Acharya, S., Singh, A., Raj, U., & Sharma, A. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_12
Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies
Milasheuskaya, V., Miraniuk, K., Sobchynskyi, M., Myrnyi, A., Kowalczuk, D., Kasianik, V., Lazitskaya, D., Turlej, K., Kiełbaszewska, I., Surosz, N., et al. (2025) · Quality in Sport · doi:10.12775/qs.2025.43.61191
Hardi, H., Fitrianti, Z., Utama, K. E., Vidya, A. P., Khatimah, N. G., Aristyo, K., Faisal, H. K. P., & Soetikno, V. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324056
Progress and Current Status of Diagnosis and Treatment of Gastrointestinal Stromal Tumor
李, 俊. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1582291
Iwata, T., Suzuki, N., Fujisawa, G., Miyakawa, Y., Tamada, K., Hayashi, T., Suzumori, C., Odawara, N., Hayakawa, Y., Sasaki, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7344606/v1
Türkel, A., Uzundal, D. E., Gürler, F., Onur, İ. D., Gülcü, S., & Arslan, Ü. Y. (2025) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1744286
Diagnostic yield: what is sufficient?
Matsumoto, Y., & Gonzalez, A. V. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001232
Clinical trial design in rare mutation tumors
Miao, Y., Li, Y., Wang, X., & Ba, Y. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00204-1
Zhang, J., Huang, H. F., Tang, B., Hu, X., Ming, Z., Wan, D., & Qu, Q. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04106-4
Malik, F., Lee, J. C., Pinto, S., Cardenas, M., Hakar, M. H., Wood, M. D., Smith, A., Hwang, S., Bagchi, A., Klimo, P., et al. (2025) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.70048
Maansson, C. T., Andersen, E. R., Ulhøi, M. P., Meldgaard, P., & Sorensen, B. S. (2023) · Figshare · doi:10.6084/m9.figshare.22626497
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Maansson, C. T., Andersen, E. R., Ulhøi, M. P., Meldgaard, P., & Sorensen, B. S. (2023) · Figshare · doi:10.6084/m9.figshare.22626494
Understanding Drug Synergy in Pancreatic Cancer: A Proteomic Study of Gemcitabine and ATR Inhibitors
Höfer, S., Küster, B., & München, T. U. (2024)
Landi, M. (2023) · Electronic Theses and Dissertations Repository (University of Pisa)
The clinical trials landscape—The future of biliary tract cancers
Passhak, M., & Valle, J. W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29287-3.00014-3
Targeted therapy in biliary tract cancer
Fiocco, C., & Spencer, K. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29287-3.00015-5
Fabregat-Franco, C. (2025) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Latif, M. U., Liu, X., Bockelmann, A., Huhnold, L., Schmídt, G., Klein, L., Zhao, X., Conradi, L., Conrads, K., Weber, A. L., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-336227
Cancer genome profiling in sarcomas: current status and future perspectives in Japan
Shimoi, T., Kita, S., & Yonemori, K. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2617407
Shen, Y., Qi, P., Wen, J., Yang, L., Zhu, L., Chen, Y., Liu, Q. Y., Wang, L., Yao, J., Li, A., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01146-6
Actionable subgroups (II): HER2+, NTRK/RET/ALK and MSI-H/TMB high
Vivas, C. S., Pena, M. B., Gimeno, D. D., & Rodríguez, J. C. R. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00135
Mutational Testing in Advanced Thyroid Cancer and Its Implications on Targeted Treatments
O’Meara, C. H., & Shonka, D. C. (2026) · Springer eBooks · doi:10.1007/978-3-032-13130-0_23
Nakashima, Y., Yokoyama, Y., Hiramatsu, K., Fukaya, M., Aoba, T., Arimoto, A., Yamashita, H., Arai, Y., & Kato, T. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2626236
Morizane, C., Matsubayashi, H., & Kanai, M. (2025) · Suizo · doi:10.2958/suizo.40.219
Hämatologische Neoplasien und solide Tumore
Ganser, A., Hertenstein, B., & Ludwig, W. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_5
Systemtherapie beim Cholangiokarzinom
Jördens, M. S., Luedde, T., & Roderburg, C. (2026) · Die Onkologie · doi:10.1007/s00761-026-01916-3
Kamış, Ş. Ç., Yağcı, B., Koç, A. S., Durak, G., & Yitik, A. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1758538
Spagnuolo, A., Spagnoletti, I., Nuccio, E., & Gridelli, C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2636928
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127
Optimisation de traitements immunothérapeutiques dans le cancer
Chavanton, A. (2024) · theses.fr (ABES) · doi:10.70675/7ea8dbe3z70b3z448fz90cez6a61ae774c59
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
